Pulmonary Flashcards
Drug class for Fluticasone
Anti-inflammatory: inhaled glucocorticoid
MoA for Fluticasone
anti-inflammatory, immunosuppresive, anti-proliferative activity
Indications for Fluticasone
asthma, COPD
SE/ADRs for Fluticasone
HA, oral thrush, URI, throat irritation, cough
Contra-indications for Fluticasone
hypersensitivity, acute bronchospasm, latent TB, glaucoma, cataracts
DX-DX interactions for Fluticasone
via inhalation minimal
Monitoring for Fluticasone
spirometry (peak flow meter)
PG category for Fluticasone
PG C
How might Fluticasone affect children?
possibly growth slowing but ‘catch up’
Drug class for Prednisone
Anti-inflammatory: oral glucocorticoid
MoA for Prednisone
anti-inflammatory early after admin by decreasing migration of WBC, reversal of capillary permeability, immunosuppressant; later onset of inhibition of protein synthesis
Indications for Prednisone
adjunct therapy in exacerbation of bronchospasms; multiple others
SE/ADRs for Prednisone
short term: minimal
longer than 10-14 days: multiple systemic
Contra-indications for Prednisone
hypersensitivity, acute bronchospasm (unless as adjunct), latent TB, glaucoma, cataracts
DX-DX interactions for Prednisone
tNSAIDs
anti-diabetic meds
anti-HTN meds
Monitoring for Prednisone
spirometry
PG category for Prednisone
caution in PG
Drug class for Cromolyn MDI
Anti-inflammatory: mast cell stabilizer
MoA for Cromolyn MDI
stabilizes mast cell membrane to prevent degranulation & release of histamine, leukotrienes, slow-rxn substance of anaphylaxis
Indications for Cromolyn MDI
childhood asthma
SE/ADRs for Cromolyn MDI
HA, unpleasant taste, hoarseness, cough
Contra-indications for Cromolyn MDI
hypersensitivity, acute asthma
DX-DX interactions for Cromolyn MDI
none
Monitoring for Cromolyn MDI
spirometry
PG category for Cromolyn MDI
PG B
Drug class for Zafirlukast
Anti-inflammatory: oral leukotriene receptor antagonist
MoA for Zafirlukast
selective & competitive antagonist of leukotriene receptors D4 & E4, SRSA
Indications for Zafirlukast
asthma
SE/ADRs for Zafirlukast
HA, N/D, hepatitis
Contra-indications for Zafirlukast
hypersensitivity
acute exacerbation of asthma
caution in alcoholic cirrhosis
DX-DX interactions for Zafirlukast
concomitant food decreases bioavailability by 40%
Monitoring for Zafirlukast
spirometry, LFT
PG category for Zafirlukast
PG B
Drug class for Salmeterol
Bronchodilator: inhaled long-acting Beta2 Adrenergic Agonist (LABA)
MoA for Salmeterol
selective, long-acting Beta2 adrenergic agonist
Indications for Salmeterol
long term control of COPD, asthma control; EIB
SE/ADRs for Salmeterol
HA, muscle pain, anxiety, insomnia
Contra-indications for Salmeterol
acute asthma/COPD; seizure d/o; CVD; diabetes, hyperthyroidism
DX-DX interactions for Salmeterol
increase levels of loop diuretics, sympathomimetics; levels increased by CYP3A4 inhibitors; impact decrease by Beta Blockers
Monitoring for Salmeterol
spirometry, HR, BP, glucose
PG category for Salmeterol
PG C
Drug class for Formoterol
Bronchodilators: inhaled long-acting Beta2 adrenergic agonist (LABA)
MoA for Formoterol
long acting Beta2 agonist
Indications for Formoterol
long term control COPD, asthma w/ steroid MDI
SE/ADRs for Formoterol
tremor, chest pain, palpitations, anxiety, insomnia, muscle cramps
Contra-indications for Formoterol
acute asthma/COPD, active CVD
DX-DX interactions for Formoterol
increase levels of loop diuretics, sympathomimetics, effect decreased by Beta Blockers
Monitoring for Formoterol
spirometry, HR, BP, glucose
PG category for Formoterol
PG C
Drug class for Albuterol
Bronchodilators: inhaled short-acting Beta2 adrenergic agonist (SABA)
MoA for Albuterol
bronchial smooth muscle Beta2 (sympathetic) receptor stimulation; racemic mix w/ R isomer active & S isomer inactive
Indications for Albuterol
bronchospasm in asthma & COPD, EIB
SE/ADRs for Albuterol
angina, increase/decrease BP, arrhythmias, palpitations, CNS stimulation, angioedema, restlessness, wakefulness
Contra-indications for Albuterol
caution w/ HTN, CHF, arrhythmias, seizure d/o, diabetes, glaucoma, hyperthyroidism, low serum K+
DX-DX interactions for Albuterol
beta blockers
Monitoring for Albuterol
spirometry
PG category for Albuterol
PG C
Drug class for Theophyline
Bronchodilators: Oral/IV PDE inhibitor/ methylxanthine
MoA for Theophyline
PDE blockade causes increased levels of cAMP which produces bronchodilation, diuresis, CNS & cardiac stimulation, release of epi
Indications for Theophyline
reversal of bronchospasm
SE/ADRs for Theophyline
tachycardia, HA, insomnia, seizures
Contra-indications for Theophyline
CVD, HTN, hyperthyroidism, peptic ulcers, seizure d/o
DX-DX interactions for Theophyline
levels increased by multiple CYP1A2, CYP3A4 inhibitor drugs
Monitoring for Theophyline
Theophylline level, spirometry, HR, BP, glucose
PG category for Theophyline
PG C
Drug class for Levalbuterol
Bronchodilators: inhaled Beta2 adrenergic agonist (SABA)
MoA for Levalbuterol
rapid acting selective Beta2 receptor agonist counteracts bronchospasm; pure R-isomer of drug
Indications for Levalbuterol
TX or prevention of bronchospasm in reversible airway disease (asthma, EIB, COPD
SE/ADRs for Levalbuterol
tremor, rhinitis, viral infection, HA, pharyngitis
Contra-indications for Levalbuterol
active cardiac disease
DX-DX interactions for Levalbuterol
increase levels of loop diuretics, sympathomimetics; levels decreased by beta blockers, combination alpha/beta blockers
Monitoring for Levalbuterol
spirometry, HR, BP
PG category for Levalbuterol
PG C
Drug class for Ipratropium HFA
Bronchodilators: inhaled anticholinergic
MoA for Ipratropium
blocks acetylcholine cholinergic receptors in bronchial smooth muscle to reduce bronchospasm
Indications for Ipratropium
acute & maintenance tx of bronchospasm in COPD, asthma
SE/ADRs for Ipratropium
URI, chest pain, palpitations, dyspepsia, xerostomia, dyspnea, flu-like syndrome
Contra-indications for Ipratropium
narrow angle glaucoma, paradoxical bronchospasm, acute asthma except in conjunction w/ SABA drug; urinary outflow obstruction
DX-DX interactions for Ipratropium
decrease effect of acetylcholinesterase inhibitors
Monitoring for Ipratropium
spirometry, HR
PG category for Ipratropium
PG C
Drug class for Tiotropium
Bronchodilators: inhaled long-acting anticholinergic
MoA for Tiotropium
blocks acetylcholine at parasympathetic receptors in bronchial smooth muscle producing bronchodilation
Indications for Tiotropium
maintenance tx bronchospasm in COPD, asthma
SE/ADRs for Tiotropium
URI, chest pain, palpitations, dyspepsia, xerostomia, dyspnea, flu-like syndrome
Contra-indications for Tiotropium
paradoxical bronchospasm, acute bronchospasm, narrow angle glaucoma, urinary tract outflow obstruction
DX-DX interactions for Tiotropium
decreases effect of acetylcholinesterase inhibitors
Monitoring for Tiotropium
spirometry, HR
PG category for Tiotripium
PG C
Drug class for Roflumilast
Phosphodiesterase 4 inhibitor
MoA for Roflumilast
drug & active metabolite inhibit PDE4 increased cAMP in inflammatory & structural cells; suppress cytokine release; inhibit lung infiltration by WBCs; decreases pulmonary remodeling
Indications for Roflumilast
adjunct therapy in COPD (chronic bronchitis)
SE/ADRs for Roflumilast
HA, wt loss, diarrhea, nausea
Contra-indications for Roflumilast
moderate to severe liver impairment
DX-DX interactions for Roflumilast
CYP3A4 inducers decrease serum concentration; Cipro increases serum concentration; Rifampin decreases concentration
Monitoring for Roflumilast
spirometry
PG category for Roflumilast
avoid use in PG
Drug class for Omalizumab
antibody agents
MoA for Omalizumab
binds to IgE antibody receptors on mast cells, blocking attachment of IgE antibody & preventing degranulation release of histamines & leukotrienes
Indications for Omalizumab
maintenance tx of allergic asthma not controlled by inhaled steroids
SE/ADRs for Omalizumab
HA, injection site rxn, URI, pain, anaphylaxis
How is Omalizumab administered?
Sub-Q every 2-4 weeks
Drug class for Nicoderm patch, Nicorette gum, Nicotrol inhaler/nasal spray
Nicotine replacement
MoA for Nicotine replacement
biphasic CNS & ANS nicotine receptor stimulant; low dose- stimulations ANS ganglia; large dose- stimulation follows by blockade of transmission
Indications for Nicotine replacement
tobacco cessation aid
SE/ADRs for Nicotine replacement
- HA, mucosal irritant, cough, rhinitis
- toxicity= tremors, respiratory excitation, convulsions, respiratory failure
Contra-indications for Nicotine replacement
recent AMI, life-threatening arrhythmias, severe angina, TMJ d/o, hyperthyroidism, T1DM, bronchospastic d/o
DX-DX interactions for Nicotine replacement
concentration increased by Cimetidine
Monitoring for Nicotine replacement
HR, BP, insomnia
PG category for Nicotine replacement
PG D (for nasal spray)
Drug class for Varenicline
partial nicotine agonist oral
MoA for Varenicline
prevents nicotine stimulation of the mesolimbic dopamine system
Indications for Varenicline
tobacco cessation aid
SE/ADRs for Varenicline
insomnia, HA, abnormal dreams, nausea
Contra-indications for Varenicline
psychiatric disorders, decreased renal function, active CVD
DX-DX interactions for Varenicline
none known
Monitoring for Varenicline
psych changes, tobacco use
PG category for Varenicline
PG C
Drug class for Bupropion
atypical antidepressant: oral dopamine reuptake inhibitor
MoA for Bupropion
unknown
Indications for Bupropion
tobacco cessation; depression
SE/ADRs for Bupropion
tachy, HA, insomnia, nausea, xerostomia, wt loss, palpitations, agitation, constipation, diarrhea
Contra-indications for Bupropion
biopolar disorder, seizure disorder, active CVD, uncontrolled HTN
DX-DX interactions for Bupropion
MAO inhibitors, ethanol
Monitoring for Bupropion
psych sxs, tobacco use, BP
PG category for Bupropion
PG C
Drug class for Umeclindinium & Vilanterol
combination inhaled long-acting anticholinergic & LABA
MoA for Umeclidinium & Vilanterol
combination of 2 agents with different bronchodilating action (anti-muscarinic & beta2 agonism)
Indications for Umeclidinium & Vilanterol
COPD
SE/ADRs for Umeclidinium & Vilanterol
paradoxical bronchospasm, chest pain, limb pain, pharyngitis
Contra-indications for Umeclidinium & Vilanterol
severe milk protein allergy, caution w/ glaucoma, comorbid thyrotoxicosis, seizure disorder, prostatic hyperplasia, low K+, diabetes
DX-DX interactions for Umeclidinium & Vilanterol
multiple but lower risk of occurrence
Monitoring for Umeclidinium & Vilanterol
FEV1, peak flow, BP, HR, CNS stimulation, eye changes
PG category for Umeclidinium & Vilanterol
PG C
Drug class for Fluticasone/Salmeterol
combination product inhaled glucocorticoid & LABA
MoA for Fluticasone/Salmeterol
anti-inflammatory action of steroid & bronchodilation activity of beta2 agonist
Indications for Fluticasone/Salmeterol
asthma (maintenance of bronchodilation), asthma
SE/ADRs for Fluticasone/Salmeterol
- combo of both drugs
- increased risk of death
Contra-indications for Fluticasone/Salmeterol
actue exacerbation of bronchospasm, status asthamticus
DX-DX interactions for Fluticasone/Salmeterol
combo of both
Monitoring for Fluticasone/Salmeterol
spirometry, HR, BP, CNS stimulation, frequency of use of SABA, growth velocity in children
PG category for Fluticasone/Salmeterol
PG C
Drug class for Ipratropium/Albuterol
combination product inhaled anticholinergic & beta2 adrenergic agonist (SABA) bronchodilators
MoA for Ipratropium/Albuterol
anticholinergic & beta2 agonist bronchodilators
Indications for Ipratropium/Albuterol
COPD patients requiring 2 bronchodilators
SE/ADRs for Ipratropium/Albuterol
combo of drugs
Contra-indications for Ipratropium/Albuterol
see individual drugs
Monitoring for Ipratropium/Albuterol
spirometry, HR, BP, frequency of use
PG category for Ipratropium/Albuterol
PG C
Drug class for Budesonide/Formoterol
combination product inhaled corticosteroid & beta2 adrenergic agonist (LABA) bronchodilators
MoA for Budesonide/Formoterol
anti-inflammatory action of steroid & bronchodilation activity of beta2 agonist
Indications for Budesonide/Formoterol
asthma (maintenance of bronchodilation), COPD
SE/ADRs for Budesonide/Formoterol
- combo of both drugs
- increased risk of death
Contra-indications for Budesonide/Formoterol
acute exacerbation of bronchospasm, status asthmaticus
DX-DX interactions for Budesonide/Formoterol
combo of both
Monitoring for Budesonide/Formoterol
spirometry, HR, BP, CNS stimulation, frequency of use of SABA, growth velocity in children